Dova Pharmaceuticals (NASDAQ:DOVA) was upgraded by equities research analysts at BidaskClub from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.
Several other research firms have also issued reports on DOVA. Leerink Swann decreased their price target on shares of Dova Pharmaceuticals from $32.00 to $31.00 and set a “market perform” rating on the stock in a research report on Tuesday, September 4th. Raymond James assumed coverage on shares of Dova Pharmaceuticals in a research report on Wednesday, August 29th. They set an “outperform” rating and a $44.00 target price on the stock. Zacks Investment Research upgraded shares of Dova Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, August 15th. Jefferies Financial Group reiterated a “buy” rating and set a $40.00 target price on shares of Dova Pharmaceuticals in a research report on Sunday, July 15th. Finally, ValuEngine upgraded shares of Dova Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, June 29th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $33.20.
NASDAQ DOVA opened at $20.27 on Friday. The company has a current ratio of 13.19, a quick ratio of 13.14 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $591.40 million, a price-to-earnings ratio of -14.48 and a beta of 0.34. Dova Pharmaceuticals has a 52-week low of $19.52 and a 52-week high of $37.00.
Dova Pharmaceuticals (NASDAQ:DOVA) last posted its quarterly earnings results on Thursday, August 9th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.07). The business had revenue of $4.58 million for the quarter. Research analysts forecast that Dova Pharmaceuticals will post -2.78 EPS for the current fiscal year.
In other Dova Pharmaceuticals news, CEO Alex Sapir bought 21,700 shares of the firm’s stock in a transaction dated Tuesday, August 14th. The shares were acquired at an average cost of $22.83 per share, for a total transaction of $495,411.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. 55.50% of the stock is currently owned by insiders.
Several institutional investors have recently modified their holdings of the company. BlackRock Inc. boosted its position in shares of Dova Pharmaceuticals by 76.5% during the 2nd quarter. BlackRock Inc. now owns 1,144,920 shares of the company’s stock valued at $34,257,000 after acquiring an additional 496,306 shares in the last quarter. Nexthera Capital LP boosted its position in shares of Dova Pharmaceuticals by 44.4% during the 2nd quarter. Nexthera Capital LP now owns 820,348 shares of the company’s stock valued at $24,545,000 after acquiring an additional 252,105 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of Dova Pharmaceuticals by 12.7% during the 2nd quarter. Wells Fargo & Company MN now owns 380,455 shares of the company’s stock valued at $11,383,000 after acquiring an additional 42,819 shares in the last quarter. Northern Trust Corp boosted its position in shares of Dova Pharmaceuticals by 154.2% during the 2nd quarter. Northern Trust Corp now owns 163,116 shares of the company’s stock valued at $4,881,000 after acquiring an additional 98,955 shares in the last quarter. Finally, Raymond James & Associates acquired a new stake in shares of Dova Pharmaceuticals during the 2nd quarter valued at about $1,465,000. Institutional investors and hedge funds own 36.57% of the company’s stock.
Dova Pharmaceuticals Company Profile
Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.
Featured Story: How is the discount rate different from the Federal Funds rate?
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.